FIVE PRIME THERAPEUTICS INC's ticker is FPRX and the CUSIP is 33830X104. A total of 176 filers reported holding FIVE PRIME THERAPEUTICS INC in Q3 2016. The put-call ratio across all filers is 10.41 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2017 | $5,000 | -99.9% | 127 | -99.9% | 0.00% | -100.0% |
Q4 2016 | $8,181,000 | -6.4% | 163,255 | -2.0% | 0.58% | +3.2% |
Q3 2016 | $8,740,000 | +24.8% | 166,509 | -1.7% | 0.56% | +16.0% |
Q2 2016 | $7,006,000 | -62.0% | 169,439 | -62.7% | 0.49% | -70.0% |
Q1 2016 | $18,451,000 | +2.4% | 454,129 | +4.6% | 1.62% | +21.4% |
Q4 2015 | $18,016,000 | +106.0% | 434,129 | -23.6% | 1.33% | +281.9% |
Q3 2015 | $8,746,000 | +57.1% | 568,258 | +153.5% | 0.35% | +4.2% |
Q2 2015 | $5,567,000 | +8.7% | 224,129 | 0.0% | 0.34% | -15.8% |
Q1 2015 | $5,121,000 | +22.2% | 224,129 | +44.4% | 0.40% | +13.1% |
Q4 2014 | $4,192,000 | +138.2% | 155,256 | +3.5% | 0.35% | +86.2% |
Q3 2014 | $1,760,000 | -24.6% | 150,000 | 0.0% | 0.19% | -17.5% |
Q2 2014 | $2,333,000 | -20.9% | 150,000 | 0.0% | 0.23% | -26.1% |
Q1 2014 | $2,949,000 | +32.5% | 150,000 | +13.2% | 0.31% | +16.1% |
Q4 2013 | $2,225,000 | – | 132,500 | – | 0.27% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 115,500 | $2,531,000 | 0.89% |
AWM Investment Company, Inc. | 150,000 | $3,288,000 | 0.64% |
BB BIOTECH AG | 827,500 | $18,139,000 | 0.51% |
Virtus ETF Advisers LLC | 17,371 | $381,000 | 0.48% |
Rock Springs Capital Management LP | 425,000 | $9,316,000 | 0.42% |
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 450,728 | $9,880,000 | 0.39% |
Telemetry Investments, L.L.C. | 44,176 | $968,000 | 0.37% |
RTW INVESTMENTS, LP | 100,377 | $2,200,000 | 0.37% |
Eventide Asset Management | 315,000 | $6,905,000 | 0.36% |
ACUTA CAPITAL PARTNERS, LLC | 52,500 | $1,151,000 | 0.22% |